New developments in the management of advanced melanoma - role of pembrolizumab.

Improta, Giuseppina; Leone, Isabella; Donia, Marco; Gieri, Stefania; Pelosi, Giuseppe; Fraggetta, Filippo

Improta, Giuseppina; Leone, Isabella; Donia, Marco; Gieri, Stefania; Pelosi, Giuseppe; Fraggetta, Filippo.

Afiliação

Improta G; Laboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Leone I; Laboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Donia M; Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
Gieri S; Laboratory of Oncologic Technologies, IBFM-CNR, Cefalù, Potenza, Italy.
Pelosi G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy ; Department of Biomedical and Clinical Sciences "Luigi Sacco", Università degli Studi di Milano, Milan, Italy.
Fraggetta F; Department of Pathology, Cannizzaro Hospital, Catania, Italy.

Onco Targets Ther ; 8: 2535-43, 2015.

Article em En | MEDLINE | ID: mdl-26396529

Palavras-chave

PD-1 inhibitor; advanced melanoma; immunotherapy; pembrolizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Itália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google